<DOC>
	<DOCNO>NCT00556699</DOCNO>
	<brief_summary>This open-label , multicenter Phase Ib study design evaluate safety , pharmacokinetics , preliminary efficacy SGN-40 combine rituximab patient relapse CD20-positive , follicular marginal zone NHL receive least one prior rituximab-containing regimen .</brief_summary>
	<brief_title>A Study SGN-40 Combination With Rituximab Patients With CD20-Positive , Follicular Marginal Zone B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Documented history histologically confirm CD20positive , follicular NHL marginal zone NHL At least one previous treatment rituxan monotherapy rituximabcontaining regimen Measurable disease Either fresh archive tumor specimen must available central confirmation diagnosis correlative study Life expectancy &gt; 3 month For patient reproductive potential , use reliable mean contraception Chemotherapy radiotherapy within 28 day Day 1 Prior treatment monoclonal antibody direct CD40 Radioimmunotherapy immunotherapy monoclonal antibody rituximab within 3 month Day 1 Prior treatment investigational drug within 28 day Day 1 Prior allogeneic bone marrow transplant Prior autologous hematopoietic stem cell transplant within 12 week Day 1 Concurrent systemic corticosteroid therapy Prior anaphylactoid serious reaction rituximab result hospitalization discontinuation therapy , Evidence clinically detectable ascites Day 1 Other invasive malignancy within 3 year prior Day 1 except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix , situ breast cancer , situ prostate cancer , cancer patient diseasefree least 3 year History evidence physical examination CNS disease Active infection require parenteral antibiotic within 14 day Day 1 Major surgical procedure ( exclude lymph node biopsy ) significant traumatic injury within 28 day prior Day 1 Pregnancy ( positive pregnancy test ) lactation Serious , nonhealing wound , ulcer , bone fracture Clinically significant cardiovascular disease , congestive heart failure , serious cardiac arrhythmia require medication within 1 year prior Day 1 . Grade II great peripheral vascular disease study entry . Known human immunodeficiency virus ( HIV ) infection Known serious medical condition , include cirrhosis , hepatitis C infection , chronic obstructive chronic restrictive pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>NHL</keyword>
	<keyword>Rituxan</keyword>
	<keyword>anti-CD40</keyword>
</DOC>